Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult…
| Price | $1.80 |
|---|---|
| Market cap | $40.68M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 1.24-10.99 |
| Beta | 0.96 |
Explore KPTI's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.